{"id":89435,"date":"2026-05-16T15:36:48","date_gmt":"2026-05-16T10:06:48","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=89435"},"modified":"2026-05-16T15:36:50","modified_gmt":"2026-05-16T10:06:50","slug":"cipla-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/","title":{"rendered":"Cipla Analyst Review May 2026"},"content":{"rendered":"<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for CIPLA at its current price of Rs 1,680. Cipla (NSE: CIPLA) is one of India&#8217;s largest pharmaceutical companies with a market capitalisation of approximately Rs 1,36,000 crore, known for its respiratory portfolio and branded generic presence across 80 plus countries. The analyst consensus target of Rs 1,900 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether CIPLA achieves that target through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Cipla_Company_Snapshot_May_2026\" title=\"Cipla Company Snapshot May 2026\">Cipla Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Analyst_Insight_in_This_Cipla_Analyst_Review\" title=\"Analyst Insight in This Cipla Analyst Review\">Analyst Insight in This Cipla Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Technical_Analysis_in_This_Cipla_Analyst_Review\" title=\"Technical Analysis in This Cipla Analyst Review\">Technical Analysis in This Cipla Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#India_Branded_Generics_Respiratory_Cardiology_Oncology\" title=\"India Branded Generics (Respiratory, Cardiology, Oncology)\">India Branded Generics (Respiratory, Cardiology, Oncology)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#US_Generics_Complex_Inhalers_and_Injectables\" title=\"US Generics (Complex Inhalers and Injectables)\">US Generics (Complex Inhalers and Injectables)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#South_Africa_and_Sub-Saharan_Africa_Branded_Business\" title=\"South Africa and Sub-Saharan Africa Branded Business\">South Africa and Sub-Saharan Africa Branded Business<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Valuation_in_This_Cipla_Analyst_Review\" title=\"Valuation in This Cipla Analyst Review\">Valuation in This Cipla Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Trade_Outlook_for_Cipla\" title=\"Trade Outlook for Cipla\">Trade Outlook for Cipla<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Key_Risks_for_Cipla_in_FY27\" title=\"Key Risks for Cipla in FY27\">Key Risks for Cipla in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Conclusion_Cipla_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Cipla Analyst Review Verdict for 2026\">Conclusion: Cipla Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Frequently_Asked_Questions_Cipla_Analyst_Review_2026\" title=\"Frequently Asked Questions: Cipla Analyst Review 2026\">Frequently Asked Questions: Cipla Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#What_is_the_analyst_target_for_Cipla_in_2026\" title=\"What is the analyst target for Cipla in 2026?\">What is the analyst target for Cipla in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Is_Cipla_a_good_investment_at_Rs_1680\" title=\"Is Cipla a good investment at Rs 1,680?\">Is Cipla a good investment at Rs 1,680?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#What_is_Ciplas_52-week_high_and_low\" title=\"What is Cipla&#8217;s 52-week high and low?\">What is Cipla&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#What_are_the_key_risks_for_Cipla\" title=\"What are the key risks for Cipla?\">What are the key risks for Cipla?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/cipla-analyst-review-2026\/#Where_can_I_get_live_data_and_analyst_targets_for_Cipla\" title=\"Where can I get live data and analyst targets for Cipla?\">Where can I get live data and analyst targets for Cipla?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_Company_Snapshot_May_2026\"><\/span><strong>Cipla Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Cipla&#8217;s branded specialty businesses in India, South Africa, and the US are growing at 15 to 20 percent. The specialty CNS products partnership and ANDA filings for complex generics in the US are catalysts for FY27 and beyond. The table below summarises the key data referenced in this <strong>Cipla analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>CIPLA<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 1,680<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,790<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 1,350<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 1,36,000 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>28.00x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 1,900<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 2,200<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 1,400<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Cipla_Analyst_Review\"><\/span><strong>Analyst Insight in This Cipla Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior Research Analyst <strong>Ankit Jaiswal<\/strong> flags Cipla as a stock to watch in May 2026. At Rs 1,680, Ankit Jaiswal notes that the key levels for CIPLA include support in the Rs 1,377 to Rs 1,596 band and resistance near Rs 1,781. He suggests watching Cipla for a potential move toward the consensus target of Rs 1,900, contingent on Pharmaceuticals sector momentum and Nifty 50 direction. Ankit Jaiswal&#8217;s view is one input in this <strong>Cipla analyst review<\/strong> and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Cipla_Analyst_Review\"><\/span><strong>Technical Analysis in This Cipla Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,680, CIPLA is trading within its 52-week band of Rs 1,350 to Rs 1,790. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 1,377 to Rs 1,596 band while resistance is seen in the Rs 1,781 to Rs 1,790 zone. A sustained move above Rs 1,781 could open the path toward the analyst consensus of Rs 1,900.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 1,377 to Rs 1,596 &#8211; investors tracking this <strong>Cipla analyst review<\/strong> should watch for a stabilisation or bounce in this range as a potential accumulation signal.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 1,781 to Rs 1,790 &#8211; a sustained close above Rs 1,781 would be a positive breakout signal worth flagging.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 1,900 represents the base-case upside for this <strong>Cipla analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"India_Branded_Generics_Respiratory_Cardiology_Oncology\"><\/span><strong>India Branded Generics (Respiratory, Cardiology, Oncology)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Cipla, directly supporting the earnings trajectory toward the consensus target of Rs 1,900.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"US_Generics_Complex_Inhalers_and_Injectables\"><\/span><strong>US Generics (Complex Inhalers and Injectables)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Cipla&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"South_Africa_and_Sub-Saharan_Africa_Branded_Business\"><\/span><strong>South Africa and Sub-Saharan Africa Branded Business<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Cipla and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Cipla_Analyst_Review\"><\/span><strong>Valuation in This Cipla Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,680, Cipla trades at a trailing P\/E of 28.00x. This <strong>Cipla analyst review<\/strong> presents three scenarios: a bull case of Rs 2,200 on strong earnings delivery, a base case of Rs 1,900 at consensus, and a bear case of Rs 1,400 if macro headwinds persist. Q1 FY27 results will be the first key validation point.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 2,200<\/td>\n<td>Strong earnings and sector tailwinds<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 1,900<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 1,400<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Cipla\"><\/span><strong>Trade Outlook for Cipla<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Cipla analyst review<\/strong>, investors might watch CIPLA near the support zone of Rs 1,377 to Rs 1,596 for potential opportunities. A flag above Rs 1,781 could suggest improving momentum toward Rs 1,900. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Cipla_in_FY27\"><\/span><strong>Key Risks for Cipla in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Cipla analyst review<\/strong> must assess downside risks. Key risks for Cipla include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in CIPLA.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Cipla_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Cipla Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Cipla analyst review<\/strong> concludes that at Rs 1,680, CIPLA offers a defined risk-reward with a consensus target of Rs 1,900. The 52-week range of Rs 1,350 to Rs 1,790 provides context on the current entry point. Use this <strong>Cipla analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on CIPLA.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Cipla_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Cipla Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Cipla_in_2026\"><\/span><strong>What is the analyst target for Cipla in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 1,900, with a bull case of Rs 2,200 and a bear case of Rs 1,400. Monitor Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Cipla_a_good_investment_at_Rs_1680\"><\/span><strong>Is Cipla a good investment at Rs 1,680?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 1,680 with a P\/E of 28.00x and a consensus target of Rs 1,900, this <strong>Cipla analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Ciplas_52-week_high_and_low\"><\/span><strong>What is Cipla&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 1,790 and the 52-week low is Rs 1,350. At Rs 1,680, CIPLA is positioned within this range as noted in this <strong>Cipla analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Cipla\"><\/span><strong>What are the key risks for Cipla?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_get_live_data_and_analyst_targets_for_Cipla\"><\/span><strong>Where can I get live data and analyst targets for Cipla?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Cipla&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cipla analyst review 2026: CMP Rs 1,680, target Rs 1,900, PE 28.00x. Technical levels, business analysis, and Pharmaceuticals sector outlook. May 2026.<\/p>\n","protected":false},"author":28,"featured_media":89593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-89435","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778926013:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_seo_score":["83"],"rank_math_primary_category":["842"],"rank_math_title":["Cipla Analyst Review 2026: Is CIPLA Worth Buying?"],"rank_math_description":["Cipla analyst review 2026: CMP Rs 1,680, target Rs 1,900, PE 28.00x. Technical levels, business analysis, and Pharmaceuticals sector outlook. May 2026."],"rank_math_focus_keyword":["Cipla Analyst Review"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["89593"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11809"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/16153524\/Cipla-Analyst-Review.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=89435"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89435\/revisions"}],"predecessor-version":[{"id":89594,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89435\/revisions\/89594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/89593"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=89435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=89435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=89435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}